[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE3880739D1 - Expression von menschlichem proapolipoprotein a-1. - Google Patents

Expression von menschlichem proapolipoprotein a-1.

Info

Publication number
DE3880739D1
DE3880739D1 DE8888870095T DE3880739T DE3880739D1 DE 3880739 D1 DE3880739 D1 DE 3880739D1 DE 8888870095 T DE8888870095 T DE 8888870095T DE 3880739 T DE3880739 T DE 3880739T DE 3880739 D1 DE3880739 D1 DE 3880739D1
Authority
DE
Germany
Prior art keywords
proapolipoprotein
sequence
expression
expression vectors
dna sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888870095T
Other languages
English (en)
Other versions
DE3880739T2 (de
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ministere de la Region Wallonne Jambes Be
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of DE3880739D1 publication Critical patent/DE3880739D1/de
Application granted granted Critical
Publication of DE3880739T2 publication Critical patent/DE3880739T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
DE8888870095T 1987-05-28 1988-05-24 Expression von menschlichem proapolipoprotein a-1. Expired - Lifetime DE3880739T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (2)

Publication Number Publication Date
DE3880739D1 true DE3880739D1 (de) 1993-06-09
DE3880739T2 DE3880739T2 (de) 1993-08-19

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888870095T Expired - Lifetime DE3880739T2 (de) 1987-05-28 1988-05-24 Expression von menschlichem proapolipoprotein a-1.

Country Status (33)

Country Link
US (1) US5059528A (de)
EP (1) EP0293357B1 (de)
JP (1) JP2634193B2 (de)
KR (1) KR970000808B1 (de)
CN (1) CN1031892C (de)
AT (1) ATE89006T1 (de)
AU (1) AU615654B2 (de)
CA (1) CA1323851C (de)
CY (1) CY1809A (de)
CZ (1) CZ283648B6 (de)
DD (1) DD291093A5 (de)
DE (1) DE3880739T2 (de)
DK (1) DK175686B1 (de)
EG (1) EG19101A (de)
ES (1) ES2054878T3 (de)
FI (1) FI100056B (de)
GB (1) GB8712540D0 (de)
HK (1) HK137794A (de)
HU (1) HU204562B (de)
IE (1) IE62422B1 (de)
IL (1) IL86480A (de)
LT (1) LT3600B (de)
LV (1) LV5288A3 (de)
NO (1) NO179253C (de)
NZ (1) NZ224808A (de)
PL (1) PL158064B1 (de)
PT (1) PT87562B (de)
RU (1) RU2009198C1 (de)
SG (1) SG131594G (de)
SK (1) SK363888A3 (de)
SU (1) SU1834904A3 (de)
UA (1) UA19765A (de)
ZA (1) ZA883824B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
DK0574402T3 (da) * 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
DK0559795T3 (da) * 1990-11-30 1996-01-29 Monoclonetics Int Fremgangsmåder til diagnosticering af kroniske smerter i lænderegionen og halshvrivelsøjlen
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
WO2002048333A2 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
KR20080049066A (ko) * 2005-08-26 2008-06-03 세레니스 쎄라퓨틱스 홀딩 에스에이 유산균에서의 아포지단백질 유전자 생성물의 생성을 위한조성물 및 방법
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
CN102239260B (zh) * 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
EP3284482B1 (de) 2008-11-10 2020-06-03 Arbutus Biopharma Corporation Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
CN104922699B (zh) 2009-03-12 2020-07-24 阿尔尼拉姆医药品有限公司 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
NZ621981A (en) 2009-05-05 2015-09-25 Tekmira Pharmaceuticals Corp Lipid compositions
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
CA3014827A1 (en) 2009-06-10 2010-12-16 Jianxin Chen Improved cationic lipid of formula i
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
EP2509636B1 (de) 2009-12-07 2017-07-19 Arbutus Biopharma Corporation Zusammensetzungen für nukleinsäurefreisetzung
EP2512449B1 (de) 2009-12-18 2019-08-07 The University of British Columbia Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP2575764B1 (de) 2010-06-03 2017-04-19 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von aktiven verbindungen
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
KR20140053848A (ko) 2011-02-07 2014-05-08 세레니스 쎄라퓨틱스 홀딩 에스에이 지단백질 복합체 및 그의 제조 및 용도
CA2849476A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
HUE050394T2 (hu) * 2013-05-01 2020-11-30 Ionis Pharmaceuticals Inc Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények
EP2853259A1 (de) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
AU2015260929A1 (en) 2014-05-02 2016-12-15 Cerenis Therapeutics Holding Sa HDL therapy markers
US11492616B2 (en) * 2016-10-27 2022-11-08 Institute Of Microbiology, Chinese Academy Of Sciences Method for modifying amino acid attenuator and use of same in production
EP3668600B1 (de) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomere
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
IL307670A (en) 2021-04-15 2023-12-01 Abionyx Pharma Sa Use of lipid-binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
WO1987002062A1 (en) 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
WO1988003175A1 (en) * 1986-10-29 1988-05-05 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii, apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
DK175686B1 (da) 2005-01-17
FI882456A (fi) 1988-11-29
IE881597L (en) 1988-11-28
JPS6416589A (en) 1989-01-20
HU204562B (en) 1992-01-28
NO179253B (no) 1996-05-28
UA19765A (uk) 1997-12-25
AU615654B2 (en) 1991-10-10
EP0293357B1 (de) 1993-05-05
AU1672388A (en) 1988-12-01
PT87562B (pt) 1992-09-30
DD291093A5 (de) 1991-06-20
ES2054878T3 (es) 1994-08-16
ATE89006T1 (de) 1993-05-15
CN88103118A (zh) 1988-12-14
IL86480A0 (en) 1988-11-15
PL272698A1 (en) 1989-03-06
NO882341D0 (no) 1988-05-27
US5059528A (en) 1991-10-22
CZ283648B6 (cs) 1998-05-13
HK137794A (en) 1994-12-16
PT87562A (pt) 1989-05-31
CZ363888A3 (cs) 1998-02-18
NZ224808A (en) 1990-01-29
NO179253C (no) 1996-09-04
SK279166B6 (sk) 1998-07-08
PL158064B1 (pl) 1992-07-31
FI882456A0 (fi) 1988-05-25
IE62422B1 (en) 1995-02-08
DE3880739T2 (de) 1993-08-19
SU1834904A3 (ru) 1993-08-15
EG19101A (en) 1994-09-29
LTIP828A (en) 1995-02-27
DK289688A (da) 1988-11-29
CN1031892C (zh) 1996-05-29
ZA883824B (en) 1989-02-22
CY1809A (en) 1995-10-20
CA1323851C (en) 1993-11-02
EP0293357A1 (de) 1988-11-30
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
KR880014110A (ko) 1988-12-22
NO882341L (no) 1988-11-29
IL86480A (en) 1992-08-18
SG131594G (en) 1995-01-13
LV5288A3 (lv) 1993-10-10
SK363888A3 (en) 1998-07-08
LT3600B (en) 1995-12-27
HUT47153A (en) 1989-01-30
KR970000808B1 (en) 1997-01-20
FI100056B (fi) 1997-09-15
JP2634193B2 (ja) 1997-07-23
RU2009198C1 (ru) 1994-03-15

Similar Documents

Publication Publication Date Title
ATE89006T1 (de) Expression von menschlichem proapolipoprotein a- 1.
ES2059354T3 (es) Un metodo para producir un polipeptido.
ATE451462T1 (de) Klonierung und expression von htlv-iii-dns
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
FI961202A (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DE69318716D1 (de) Anti-Katze Immundefiziensvirus (FIV) Impfstoffe
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
DK27097A (da) Minactivin og fremgangsmåde til fremstilling deraf
ATE87977T1 (de) Herstellung menschlichen somatomedins c.
DE3856392D1 (de) Klonierung von Malaria-spezifischen DNA-Sequenzen:Isolierung des Gens für das 140 kd Protein
TH5997EX (th) การสร้างโปรอโปดิโปรโปรตีน a-i ของคนโดยการแสดงออกของรหัสพันธุกรรม

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MINISTERE DE LA REGION WALLONNE, JAMBES, BE